Information Provided By:
Fly News Breaks for January 26, 2016
VRTX
Jan 26, 2016 | 07:29 EDT
After conducting checks with cystic fibrosis doctors, Stifel says the checks indicate that the Street's worries regarding Orkambi uptake, adherence, and persistence are overdone. The firm remains upbeat on the drug's longer term outlook and keeps a $160 price target and Buy rating on the shares.